Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
PEL will explore the PLI scheme and apply if its beneficial.
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
Subscribe To Our Newsletter & Stay Updated
